3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Small Cell Lung Carcinoma
2
Recurrence
2
Meningioma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer
1
Lung Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
DLBCL
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
Nivolumab
143
pembrolizumab
129
Sunitinib
127
Bevacizumab
71
Everolimus
70
Sorafenib
68
cabozantinib
64
Ipilimumab
61
pazopanib
58
Axitinib
57
aldesleukin
51
Magnetic Resonance Spectroscopy
43
Cyclophosphamide
40
Interleukin-2
38
lenvatinib
36
Radiosurgery
36
Specimen Handling
33
Interferon-alpha
32
atezolizumab
29
belzutifan
24
temsirolimus
23
Gemcitabine
23
fludarabine phosphate
22
Radiotherapy
18
Interferon alpha-2
18
Biopsy
18
fludarabine
17
durvalumab
17
avelumab
17
Paclitaxel
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Renal Cell
×
vistusertib
×
Clear all
NCT01793636
2014-06-24
ZEBRA
Queen Mary University of London
Phase 2
Terminated
49 enrolled